We engineered the BLISH, which included metastatic melanoma spheroids with a perfusable BV and LV pair, to evaluate the effect of administration of the BRAF and PI3K inhibitors on melanoma intravasation (Figure 5Ai). This evidence concerns the gene BRAF and metastatic melanoma.